Navigation Links
Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions
Date:6/2/2008

OSAKA, Japan and UNION CITY, Calif., June 2 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. and MacuSight, Inc. today announced that the two companies have entered into a research and development collaboration and license agreement for the Japanese and Asian development and commercialization of sirolimus for the treatment of ocular diseases and conditions including wet age related macular degeneration (wet AMD) and diabetic macular edema (DME). Sirolimus, originally known as rapamycin, is a highly-potent, broad-acting compound that has demonstrated the ability to combat a broad range of diseases and conditions. MacuSight is presently initiating a Phase 2 clinical trial of sirolimus in DME and preparing to initiate a Phase 2 study in wet AMD in the second half of 2008.

Under terms of the agreement, Santen receives rights to develop and commercialize sirolimus for ocular diseases and conditions in Japan and Asia. MacuSight retains development and commercialization rights to sirolimus in all other markets. While specific financial details of the agreement have not been disclosed, Santen has agreed to provide MacuSight with an initial upfront payment of $50 million dollars for funding MacuSight's continuing research and development efforts, as well as clinical development of sirolimus. Additionally, Santen will provide MacuSight with milestone payments and a royalty on future sirolimus sales in the Japanese and Asian markets.

"We believe that this deal represents tremendous validation for our sirolimus development program and signals a critical corporate milestone in the history of MacuSight," stated David A. Weber, Ph.D., president and chief executive officer of MacuSight. "We are thrilled to be able to partner this program with a company of Santen's experience, particularly as it relates to developing and commercializing pharmaceuticals in Japan and Asia. We look forward to a long and productive relationship with our new collaborators."

Sir
'/>"/>

SOURCE MacuSight, Inc.; Santen Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
2. GeneNews announces management changes to support commercialization of ColonSentry(TM)
3. AMDL Announces New GOODNAK Consumer Anti-Aging Products for Use in Skin Renewal Treatments
4. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
5. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
6. Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
7. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
8. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
9. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
10. Favrille Announces Workforce Reduction
11. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... DIEGO , May 16, 2013  The registration ... of Bioscience Financial Officers (ABFO) 2013 National Conference, the ... be held May 28-31 at the Hilton San Diego ... touches on this year,s conference and want to make ... to attend," said Brandi Roberts , ...
(Date:5/16/2013)... May 16, 2013 As the weather warms, ... their favorite Spring looks. While most make a statement with ... many women find the warmer weather mixes makeup and sweat ... with the onset of acne during warmer months, Adult ... acne treatment users the best ways to deter breakouts. ...
(Date:5/16/2013)... NEW YORK , May 16, ... a new market research report is ...   Competitor Analysis: ... Biosuperiors http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The ...
(Date:5/16/2013)... 2013 BioInformatics LLC New Market Report ... Cell-Derived Cells: Current and Future Opportunities (13-004) , ... in the primary cells market continues to increase. In ... used most often, how satisfied scientists are with commercially ... anticipated growth rate. ,  , Additionally, terminally differentiated ...
Breaking Biology Technology:Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... - Johnson & Johnson Diabetes Institute Launched ... Key Role in Halting Escalating,Disease in the EMEA ... the number of people with diabetes,will have increased ... within Eastern,Mediterranean and Middle Eastern populations and 80 ...
... Sept. 24 InVitria,( http://www.InVitria.com ) addressed ... Cell Culture Development" Conference on,September 15-16 in ... optimizing cell culture media using its product ... ), In a presentation of scientific ...
... (Nasdaq: MATK ) --,Martek Biosciences Corporation ... sole source supply agreement with Grupo Ricap. Martek ... produced by Grupo Ricap in,Mexico. Grupo Ricap is ... & life,sARA(TM) will initially be available in infant,formula ...
Cached Biology Technology:Health Experts Call for New Strategies to Combat Alarming Rise in Diabetes 2Health Experts Call for New Strategies to Combat Alarming Rise in Diabetes 3Health Experts Call for New Strategies to Combat Alarming Rise in Diabetes 4InVitria Touts Product Advantages at Cambridge's Cell Culture Conference 2Martek to be the Sole Source Supplier of DHA and ARA for Infant Formulas Produced By Grupo Ricap 2
(Date:5/16/2013)... years old give unprecedented insight into the evolutionary ... most species-rich groups among the modern bony fishes. ... from the Division of Paleontology and Geobiology at ... Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have completed ... assign to the group of bony fishes that ...
(Date:5/16/2013)... Cameroon and the manager of San Diego Zoo Global,s ... Whitley award. The Whitley award is an international ... it celebrates the extraordinary achievements of some of the ... was selected for the award due to his efforts ... its wildlife inhabitants., HRH The Princess Royal, the charity,s ...
(Date:5/15/2013)... studies touting its benefit in moderating gout risk, new ... does not reduce uric acid (urate) levels to a ... C supplementation, alone or in combination with allopurinol, appears ... levels in gout patients according to the results published ... Arthritis & Rheumatism . , Gout is an ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Academies today announced the recipients of their 2009 Communication ... INITIATIVE, these prestigious awards recognize excellence in reporting and ... With support from the W.M. Keck Foundation, the ... This year,s winners will be honored during a ...
... Boston, with the Broad Institute and Harvard Medical School, ... National Institute of Mental Health as part of the ... with autism, using new technologies for rapid DNA sequencing ... grant, part of the federal stimulus package, officially starts ...
... of Massachusetts Medical School today announced the beginning of ... activity of a human monoclonal antibody (MAB) developed to ... being conducted at the King Edward Memorial Hospital in ... of India, which is working in a collaborative partnership ...
Cached Biology News:Academies announce winners of 2009 Communication Awards 2Academies announce winners of 2009 Communication Awards 3Stimulus grant to fund whole-genome sequencing in children with autism 2Stimulus grant to fund whole-genome sequencing in children with autism 3First human gets new antibody aimed at rabies virus 2First human gets new antibody aimed at rabies virus 3
For testing the AQUA technique on your MS instruments....
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... assay (ELISA) test kits are qualitative ... the detection of drugs and/or their metabolites ... for forensic use only. It is recommended ... a quantitative method such as GC/MS. ...
Biology Products: